The company's management has considerable experience in managing the interaction of researchers and marketing, the synergy of which makes for successful product development. The interaction between researchers and the medical community is also another area of significant experience in Celtic’s management.
Dr. Paul F. Reid, co-founder, seed investor and current Managing Director. He has a PhD in Neurobiochemistry from Imperial College, London, and BA in Microbiology from Trinity College, Dublin. He is a leading world expert in the therapeutic use of snake venom neurotoxins. Paul is widely experienced in USA medical regulatory affairs and FDA protocols. He was previously manager of Receptopharm, Inc., a Florida based SME specialising in therapeutic venom technologies. He has extensive experience in drug production, new drug development, clinical trial design, and experimental design. Paul is based in the USA since 1993, where he has built in-depth knowledge of US regulatory requirements.
John Reid, co-founder and seed investor, has a master’s degree in International Business Management from Trinity College, Dublin. John is a director and company secretary. Having succeeded in procuring initial seed capital and developing R&D and consultancy agreements, he successfully coordinated the vital start-up activities of early funding and angel investments, information dissemination, and liaison with legal, financial, medical and scientific advisors in Ireland. John is based in Ireland where the Company is incorporated and where he is director of operations.
In addition to Dr. Reid, the Company has assembled a Board of Advisors comprising the following renowned experts: